EyeBio CEO David Guyer (L) and CSO Anthony Adamis

Eye­Bio dou­bles the size of its Se­ries A as an­ti-VEGF vet­er­ans seek new ways of treat­ing reti­nal dis­eases

Reti­nal dis­ease biotech Eye­Bio has dou­bled the size of its ini­tial Se­ries A raise from Feb­ru­ary 2022. With an­oth­er $65 mil­lion, the biotech will fur­ther test its Wnt ag­o­nist and bring a sec­ond as­set in­to the clin­ic next year, CEO David Guy­er told End­points News on Tues­day morn­ing.

The Se­ries A ex­ten­sion ar­rives a few weeks af­ter the field’s biggest con­fab, the Amer­i­can Acad­e­my of Oph­thal­mol­o­gy an­nu­al meet­ing, and comes af­ter a string of fi­nanc­ing rounds that has buoyed oth­er star­tups in the space.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.